Cyclacel Pharmaceuticals (CYCC) Earnings Date, Estimates & Call Transcripts $0.21 -0.02 (-6.96%) Closing price 03:59 PM EasternExtended Trading$0.21 0.00 (-0.47%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cyclacel Pharmaceuticals Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 7After Market ClosesEstimatedActual EPS (Apr. 2) -$0.33 Missed By -$0.04 Consensus EPS (Apr. 2) -$0.29 Cyclacel Pharmaceuticals posted Q4 2024 earnings on April 2, 2025, reporting an EPS of -$0.33, which missed the consensus estimate of -$0.29 by $0.04. Quarterly revenue was reported to be $0.01 million, below analysts' expectations of $0.01 million. Cyclacel Pharmaceuticals currently has a trailing EPS of -$9.40CYCC Upcoming EarningsCyclacel Pharmaceuticals' next earnings date is estimated for Wednesday, May 7, 2025, based off prior year's reporting schedules. Get Cyclacel Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCYCC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CYCC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Cyclacel Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.29-$0.29-$0.29Q2 20251-$0.30-$0.30-$0.30Q3 20251-$0.30-$0.30-$0.30Q4 20251-$0.30-$0.30-$0.30FY 20254($1.19)($1.19)($1.19) Remove Ads Cyclacel Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/7/2025(Estimated)-------4/2/2025Q4 2024-$0.29-$0.33 -$0.04-$0.33$0.01M$0.01M11/12/2024--$0.54-$0.18+$0.36-$0.18$0.01M$0.01M8/14/2024Q2 2024-$0.83-$0.72+$0.11-$0.72$0.03M-5/14/2024Q1 2024-$4.93-$2.27+$2.66-$2.27-$0.03M3/19/2024Q4 2023-$6.35-$6.23+$0.12-$6.23-$0.03M11/13/2023Q3 2023-$5.70-$7.35 -$1.65-$0.49-$0.02M8/9/2023Q2 2023-$8.10-$6.60+$1.50-$0.44-$0.37M5/11/2023Q1 2023-$10.20-$7.05+$3.15-$0.47-- More Earnings Resources from MarketBeat Related Companies Omega Therapeutics Earnings Hoth Therapeutics Earnings Cyclerion Therapeutics Earnings Dogwood Therapeutics Earnings BioXcel Therapeutics Earnings Mainz Biomed Earnings Alzamend Neuro Earnings Klotho Neurosciences Earnings AEON Biopharma Earnings Dermata Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Remove Ads This page (NASDAQ:CYCC) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
